3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
5
Breast
4
Gastrointestinal
3
Sarcoma
2
Gynecologic
2
Thoracic
1
Conditions
Breast Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Liposarcoma
1
Colorectal Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Docetaxel
19
pembrolizumab
14
Surveys and Questionnaires
7
Radiotherapy
7
Paclitaxel
7
Magnetic Resonance Spectroscopy
7
Gemcitabine
7
Standard of Care
6
Specimen Handling
6
Radiosurgery
6
Psychiatric Rehabilitation
6
Early Intervention, Educational
6
Trastuzumab
5
Nivolumab
5
enzalutamide
4
Interviews as Topic
4
motexafin gadolinium
3
cabozantinib
3
X-Rays
3
Sirolimus
3
Methods
3
Educational Status
3
Cisplatin
3
Carboplatin
3
Azacitidine
3
tisotumab vedotin
2
rucaparib
2
pertuzumab
2
pegilodecakin
2
palbociclib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Letrozole
×
Thoracic
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled